Sharemaestro company-news research for GRAIL, LLC (GRAL), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Measured evidence

Company news sentiment

GRAL news sentiment

GRAIL, LLC

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research Options activity RSS feed
30-day score27Neutral is 50
Cautious news tone 54/100 evidence confidence 100% direct company focus 56 current stories across 17 publishers
Latest weekly closeUSD 69.48week of 7 Aug 2026
Main news subjectRegulatory and legal87/100 share of current news
News data statusPartial30 duplicate stories removed

Current company news

Cautious news tone

The score uses 56 current company stories from 17 publishers.

Observed headline tone19/100 Published 30-day score27/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline GRAIL Inc Revenue Breakdown – LSX:A40F8M TradingView · 08 Aug 2026 18:40

What supports the score

Direct evidence

56 current stories are mapped specifically to GRAL.

Source breadth

The score uses 17 publishers rather than depending on one outlet.

Story agreement

The current stories agree at 90/100.

Price response

Cautious headlines are being absorbed by price, which can signal underlying demand.

What limits the score

No major limit stands out.

27/100
News scoreCautious news tone
55/100
Confidencebuilding confidence
100%/100
Company news56 company stories
90/100
Story agreement10/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
16 Jul: 8 stories17 Jul: 2 stories18 Jul: 1 stories19 Jul: 1 stories20 Jul: 3 stories21 Jul: 5 stories22 Jul: 2 stories23 Jul: 3 stories24 Jul: 7 stories27 Jul: 4 stories28 Jul: 4 stories29 Jul: 4 stories30 Jul: 4 stories31 Jul: 1 stories04 Aug: 3 stories08 Aug: 2 stories 16 Jul: tone 16, 8 stories17 Jul: tone 20, 2 stories18 Jul: tone 33, 1 stories19 Jul: tone 15, 1 stories20 Jul: tone 15, 3 stories21 Jul: tone 17, 5 stories22 Jul: tone 16, 2 stories23 Jul: tone 16, 3 stories24 Jul: tone 24, 7 stories27 Jul: tone 20, 4 stories28 Jul: tone 36, 4 stories29 Jul: tone 16, 4 stories30 Jul: tone 20, 4 stories31 Jul: tone 10, 1 stories04 Aug: tone 16, 3 stories08 Aug: tone 50, 2 stories 95505
16 Jul31 Jul14 Aug
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence54
2.694 after freshness weighting
Source breadth100
17 independent publishers
Company relevance100
share tied directly to this company
Freshness8
recency-weighted evidence
Agreement90
how closely stories agree
Publisher mix66
less reliance on one publisher

Price and news history

News score and weekly price over 26 weeks

Bad news being absorbed

Cautious headlines are being absorbed by price, which can signal underlying demand.

One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
13 Feb 2026: close 97.5, indexed 100.020 Feb 2026: close 50.21, indexed 51.527 Feb 2026: close 53.23, indexed 54.606 Mar 2026: close 50.23, indexed 51.513 Mar 2026: close 43.06, indexed 44.220 Mar 2026: close 46.84, indexed 48.027 Mar 2026: close 48.49, indexed 49.703 Apr 2026: close 54.99, indexed 56.410 Apr 2026: close 45.63, indexed 46.817 Apr 2026: close 51.71, indexed 53.024 Apr 2026: close 54.42, indexed 55.801 May 2026: close 54.06, indexed 55.408 May 2026: close 61.64, indexed 63.215 May 2026: close 59.65, indexed 61.222 May 2026: close 67.19, indexed 68.929 May 2026: close 71.68, indexed 73.505 Jun 2026: close 59.98, indexed 61.512 Jun 2026: close 59.85, indexed 61.419 Jun 2026: close 63.74, indexed 65.426 Jun 2026: close 65.92, indexed 67.603 Jul 2026: close 69.11, indexed 70.910 Jul 2026: close 72.0, indexed 73.817 Jul 2026: close 72.62, indexed 74.524 Jul 2026: close 67.84, indexed 69.631 Jul 2026: close 68.56, indexed 70.307 Aug 2026: close 69.48, indexed 71.3 26 Jun 2026: news score 50, close 65.92, 4 stories5003 Jul 2026: news score 47, close 69.11, 8 stories4710 Jul 2026: news score 49, close 72.0, 12 stories4917 Jul 2026: news score 27, close 72.62, 26 stories2724 Jul 2026: news score 23, close 67.84, 46 stories2331 Jul 2026: news score 24, close 68.56, 60 stories2407 Aug 2026: news score 25, close 69.48, 57 stories25
13 Feb15 May07 Aug
Weekly close, indexedSentiment score
26-week price-28.7%latest close 69.48
News score change-25first to latest comparable week
One-week response+1.3%Price digesting
Fair-value position+51.5%Materially above fair value
WeekNews scoreCloseWeekly move
07 Aug 202625USD 69.48+1.3%
31 Jul 202624USD 68.56+1.1%
24 Jul 202623USD 67.84-6.6%
17 Jul 202627USD 72.62+0.9%
10 Jul 202649USD 72.0+4.2%
03 Jul 202647USD 69.11+4.8%
26 Jun 202650USD 65.92+3.4%
Caution agrees with inactive trend

News subjects

What is shaping the score

Regulatory and legal
Regulatory and legal1742 stories · 75%
Market update496 stories · 11%
Earnings506 stories · 11%
Guidance371 stories · 2%
Deals and strategy571 stories · 2%

Source mix

Where the evidence comes from

66/100 independence
GlobeNewswire1818 stories · 32%
PR Newswire147 stories · 12%
TradingView335 stories · 9%
Stock Titan545 stories · 9%
Morningstar143 stories · 5%
The National Law Review153 stories · 5%
TMX Newsfile132 stories · 4%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences53Finance48Financial Markets17Earnings10

Earlier readings

How the score has changed

31 comparable readings · 52 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move-2150 to 29 · Weakening
Observed range22–5050 is the neutral baseline
Evidence depth57stories at latest stored reading · +56
Confidence47/100Measured · +19
22 Jun50 neutral14 Aug 00:59
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
14 Aug 00:5929+347/100 (-14)57 (-2)Measured
08 Aug 23:5926+261/100 (-9)59 (0)Measured
04 Aug 23:5924+070/100 (-4)59 (-1)Measured
31 Jul 23:5924-174/100 (-1)60 (+1)Measured
30 Jul 23:5925+075/100 (+1)59 (+3)Measured
29 Jul 23:5925+074/100 (0)56 (+3)Measured
28 Jul 23:5925+174/100 (0)53 (+4)Measured
27 Jul 23:5924+174/100 (-2)49 (+3)Measured

Source headlines

The news behind the score

Showing 1-30 of 56

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#150Tone
TradingViewDirect company coverageStored article

GRAIL Inc Revenue Breakdown – LSX:A40F8M

GRAIL Inc (LSX:A40F8M) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top-performing "Screening" segment, an increase from 104.93 million EUR in the previous year. The United States was the largest geographical contributor, accounting for 116.72 million EUR in revenue.

EarningsLife Sciences
Published
08 Aug 2026 18:40
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.7% · 5.4d old
Duplicates
1 consolidated
#314Tone
Eagle-TribuneDirect company coverageStored article

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP is investigating potential securities claims against Grail, Inc. (NASDAQ: GRAL) and reminds investors that the deadline to seek the role of lead plaintiff in a federal securities class action lawsuit is August 4, 2026. The lawsuit alleges that Grail made false and misleading statements regarding the success likelihood of its NHS-Galleri trial, leading to a significant stock price drop after the company announced its primary endpoint was not met. Investors who purchased GRAL stock between May 13, 2024, and February 19, 2026, and suffered losses are encouraged to contact the firm.

FinanceLife Sciences
Published
04 Aug 2026 18:41
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 6.7% · 9.4d old
Duplicates
1 consolidated
#425Tone
GlobeNewswireDirect company coverageStored article

Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Grail, Inc. (NASDAQ: GRAL) who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail made misleading statements and concealed material adverse facts regarding the true state of its NHS-Galleri trial, specifically concerning the sufficiency of the trial period to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the firm to discuss their legal rights.

FinanceLife Sciences
Published
04 Aug 2026 13:41
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 4.9% · 9.6d old
Duplicates
1 consolidated
#510Tone
PR NewswireDirect company coverageStored article

GRAL DEADLINE TODAY: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL), urging investors with substantial losses to join before the August 4, 2026, lead plaintiff deadline. The lawsuit alleges that GRAIL and its executives misled investors about the NHS-Galleri cancer screening trial's design and efficacy, particularly concerning the sufficiency of its three-year follow-up period. GRAIL's stock plummeted by 50.55% on February 19, 2026, after the company disclosed that the trial failed to meet its primary endpoint and admitted to a flawed timeline, leading to over $2.2 billion in market cap loss.

Life SciencesFinancial MarketsFinance
Published
04 Aug 2026 09:41
News subject
Regulatory and legal
Why this score
Failed To Meet, Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 6.5% · 9.8d old
Duplicates
1 consolidated
#610Tone
GlobeNewswireDirect company coverageStored article

$GRAL Securities: Suffer Losses on Your GRAIL, Inc.

Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet its primary endpoint. Investors who suffered losses are encouraged to contact BFA Law before the August 4, 2026, lead plaintiff deadline.

EarningsFinanceFinancial MarketsLife Sciences
Published
31 Jul 2026 06:46
News subject
Regulatory and legal
Why this score
Failed To Meet, Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 5.5% · 13.9d old
Duplicates
1 consolidated
#750Tone
Stock TitanDirect company coverageStored article

GRAIL to Present at the Canaccord Genuity 46th Annual Growth Conference

GRAIL (Nasdaq: GRAL) announced that its management will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, at 10:00 a.m. ET. Live and replay webcasts of the presentation will be available through GRAIL's investor relations website, with the replay archived for at least 30 days. This event provides investors with an opportunity to learn more about GRAIL's mission to detect cancer early.

FinanceLife Sciences
Published
30 Jul 2026 20:10
News subject
Market update
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 14.4d old
Duplicates
2 consolidated
#825Tone
Business WireDirect company coverageStored article

GRAL Deadline: Rosen Law Firm Urges GRAIL, Inc. (NASDAQ: GRAL) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm is notifying stockholders of GRAIL, Inc. (NASDAQ: GRAL) about a class action lawsuit for alleged misleading statements made between May 13, 2025, and February 19, 2026. The lawsuit claims GRAIL concealed material adverse facts regarding its NHS-Galleri trial's sufficiency to demonstrate a reduction in Stage III-IV cancers. Shareholders have until August 4, 2026, to file as lead plaintiff.

Life SciencesFinance
Published
30 Jul 2026 17:10
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 3% · 14.5d old
Duplicates
1 consolidated
#925Tone
GlobeNewswireDirect company coverageStored article

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in Grail’s NHS-Galleri trial, thereby harming investors. Investors who purchased Grail securities between May 13, 2025, and February 19, 2026, are encouraged to join the class action, with a lead plaintiff deadline of August 4, 2026.

Life SciencesFinance
Published
30 Jul 2026 16:10
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 3% · 14.5d old
Duplicates
1 consolidated
#1014Tone
MorningstarDirect company coverageStored article

Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld crucial internal data suggesting the NHS-Galleri trial's three-year design was insufficient to achieve its primary endpoint, leading to a significant stock price drop when the trial failed. Investors who suffered losses are encouraged to contact the firm to recover damages.

EarningsFinanceLife Sciences
Published
30 Jul 2026 11:11
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 5.4% · 14.7d old
Duplicates
3 consolidated
#1150Tone
TradingViewDirect company coverageStored article

GRAIL to Announce Second Quarter 2026 Financial Results

GRAIL, Inc. (Nasdaq: GRAL) announced it will release its second-quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. Interested parties can find a link to the live webcast and recorded replay on the investor relations section of GRAIL's website.

EarningsLife Sciences
Published
29 Jul 2026 23:39
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.4% · 15.2d old
Duplicates
1 consolidated
#1214Tone
GlobeNewswireDirect company coverageStored article

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Rol

Bragar Eagel & Squire, P.C. has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) for allegedly making false and misleading statements regarding its NHS Galleri trial. Investors who purchased GRAIL common stock between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the firm by August 4, 2026, to discuss potentially becoming lead plaintiff. The lawsuit claims GRAIL concealed issues with the trial's ability to demonstrate a reduction in Stage III-IV cancers, leading to a significant stock price drop after negative trial results were revealed on February 19, 2026.

FinanceLife Sciences
Published
29 Jul 2026 22:09
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 4.2% · 15.3d old
Duplicates
2 consolidated
#1350Tone
Stock TitanDirect company coverageStored article

GRAIL webcast on Aug. 5 results open to all interested parties

GRAIL (Nasdaq: GRAL) will announce its second quarter 2026 financial results after market close on Wednesday, August 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results and business progress. The live webcast and recorded replay will be accessible via the investor relations section of GRAIL's website, and interested participants are encouraged to register in advance.

EarningsLife Sciences
Published
29 Jul 2026 20:11
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.4% · 15.4d old
Duplicates
1 consolidated
#1412Tone
GlobeNewswireDirect company coverageStored article

GRAL Court Deadline: GRAIL, Inc. Investor Deadline in Securities Fraud Class Action is August 4 – Contact BFA Law if You Lost Money

Bleichmar Fonti & Auld LLP has announced a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, which caused a 50.55% stock drop on February 20, 2026, after the trial failed to meet its primary endpoint. Investors who lost money are encouraged to contact BFA Law by the lead plaintiff deadline of August 4, 2026.

EarningsFinanceFinancial MarketsLife Sciences
Published
29 Jul 2026 10:17
News subject
Regulatory and legal
Why this score
Failed To Meet, Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 4.5% · 15.8d old
Duplicates
1 consolidated
#1557Tone
Stock TitanDirect company coverageStored article

BlackRock (GRAL holder) discloses 7.9% GRAIL, Inc. stake in 13G/A

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 7.9% passive ownership stake in GRAIL, Inc. (GRAL). This ownership amounts to 3,376,085 shares of GRAIL common stock, with BlackRock holding sole voting power over 3,312,474 shares and sole dispositive power over all 3,376,085 shares. The filing indicates that no single client of BlackRock exceeds five percent of GRAIL's outstanding common shares.

FinanceFinancial MarketsLife Sciences
Published
28 Jul 2026 21:41
News subject
Deals and strategy
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Low · 0.7% · 16.3d old
Duplicates
1 consolidated
#1625Tone
Carroll County Mirror-DemocratDirect company coverageStored article

Portnoy Law Firm Announces Class Action on Behalf of Grail, Inc. Investors

The Portnoy Law Firm has announced a class action lawsuit against Grail, Inc. (NASDAQ: GRAL) on behalf of investors who purchased securities between May 13, 2025, and February 19, 2026. The lawsuit alleges that Grail disseminated materially false and misleading statements regarding its NHS-Galleri trial, concealing that the trial design was insufficient to demonstrate a reduction in Stage III-IV cancers within the specified follow-up period. Investors have until August 4, 2026, to file a lead plaintiff motion.

FinanceLife Sciences
Published
28 Jul 2026 15:41
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.2% · 16.6d old
Duplicates
2 consolidated
#1740Tone
PR NewswireDirect company coverageStored article

Lost Money on GRAIL, Inc. (GRAL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm

The Gross Law Firm has issued a notice to shareholders of GRAIL, Inc. (NASDAQ: GRAL) who purchased shares between May 13, 2025, and February 19, 2026. The firm encourages these shareholders to join a class action lawsuit seeking recovery, stating that the company allegedly provided false and misleading statements regarding its NHS-Galleri trial's potential to reduce Stage III-IV cancers. Following the announcement that the trial's primary endpoint was not met, GRAIL's stock price dramatically declined by over 50% in one day.

Life SciencesFinance
Published
28 Jul 2026 13:41
News subject
Market update
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 16.6d old
Duplicates
1 consolidated
#1844Tone
ACCESS NewswireDirect company coverageStored article

Pomerantz LLP Shares Class Action Details With Investors in GRAIL, Inc. – GRAL

Pomerantz LLP has announced a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) following a significant drop in its stock price. The lawsuit stems from Grail's announcement on February 19, 2026, that its NHS-Galleri Trial did not meet its primary endpoint, leading to a more than 50% decline in stock value. Investors who purchased Grail securities during the Class Period have until August 4, 2026, to seek appointment as Lead Plaintiff.

FinanceLife Sciences
Published
28 Jul 2026 07:40
News subject
Regulatory and legal
Why this score
Legal victory, Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.5% · 16.9d old
Duplicates
1 consolidated
#1925Tone
wahanariau.comDirect company coverageStored article

GRAL DEADLINE ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, about the August 4, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that GRAIL made materially false and misleading statements and/or concealed material adverse facts regarding its NHS-Galleri trial, specifically concerning its sufficiency to demonstrate a reduction in Stage III-IV cancers. Investors are encouraged to contact the Rosen Law Firm to join the class action and potentially recover damages.

Life SciencesFinance
Published
27 Jul 2026 22:50
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2% · 17.3d old
Duplicates
1 consolidated
#2050Tone
GlobeNewswireDirect company coverageStored article

$GRAL Lawsuit Notice: BFA Law Reminds GRAIL, Inc. Investors

BFA Law has filed a securities fraud class action lawsuit against GRAIL, Inc. following a 50% stock drop. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial by making positive statements about the trial's design and results, despite the three-year timeframe being insufficient to demonstrate the primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case.

FinanceLife SciencesFinancial Markets
Published
27 Jul 2026 11:40
News subject
Regulatory and legal
Why this score
Legal victory, Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.2% · 17.7d old
Duplicates
1 consolidated
#2113Tone
TMX NewsfileDirect company coverageStored article

AUGUST 4, 2026 GRAL DEADLINE: GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces a shareholder class action lawsuit against GRAIL, Inc. and its executives for alleged Securities Exchange Act violations. The lawsuit claims that Grail made false and misleading statements regarding its NHS-Galleri trial's primary endpoint, which was not achieved, leading to a significant stock price drop. Investors who suffered substantial losses between

FinanceLife Sciences
Published
27 Jul 2026 10:40
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 3% · 17.8d old
Duplicates
2 consolidated
#2212Tone
ACCESS NewswireDirect company coverageStored article

GRAIL, Inc. ($GRAL) Investors Notified of August 4 Court Deadline in Securities Fraud Lawsuit Over Trial Results Allegations

A class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and its executives for securities fraud, stemming from a significant stock drop after the NHS-Galleri cancer trial failed to meet its primary endpoint. Investors have until August 4, 2026, to seek lead plaintiff status in the case, which alleges the company made misleading statements about the trial's design and results. The lawsuit claims GRAIL's stock fell over 50% following the announcement that the trial did not show a statistically significant reduction in late-stage cancers.

Life SciencesFinance
Published
27 Jul 2026 03:40
News subject
Regulatory and legal
Why this score
Failed To Meet, Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 3.1% · 18.1d old
Duplicates
1 consolidated
#2350Tone
TradingViewDirect company coverageStored article

GRAIL Inc Revenue Breakdown – HAN:NL0

GRAIL Inc (NL0) generated 125.31 million EUR in revenue last year. The majority of this revenue, 118.01 million EUR, came from its top segment, Screening, showing an increase from the previous year's 104.93 million EUR. The United States was the largest contributor to the company's revenue, accounting for 116.72 million EUR.

EarningsLife SciencesFinancial Markets
Published
24 Jul 2026 22:41
News subject
Earnings
Why this score
No clear positive or negative phrase
Company focus
Shared story · 78%
How it is used
Direct company coverage
Weighted influence
Low · 0.1% · 20.3d old
Duplicates
1 consolidated
#2443Tone
MedCity NewsDirect company coverageStored article

Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail

Priority Health has partnered with Color Health and Grail to introduce two new cancer support solutions for self-funded employers. These solutions, available from January 1, 2027, will offer virtual cancer navigation, support, and multi-cancer early detection to Priority Health's 1.4 million members. The aim is to proactively address cancer earlier, provide personalized support, and potentially reduce healthcare costs associated with late-stage diagnoses.

Life SciencesFinance
Published
24 Jul 2026 17:41
News subject
Market update
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · <0.1% · 20.5d old
Duplicates
1 consolidated
#2516Tone
lincolnjournal.comDirect company coverageStored article

GRAL Shareholder Alert: GRAIL, Inc. Securities Class Action Lawsuit - Investors Should Contact The Gross Law Firm

The Gross Law Firm has issued a shareholder alert for investors of GRAIL, Inc. (GRAL), announcing a securities class action lawsuit. Investors who purchased GRAL shares between May 13, 2020, and February 19, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment. The lawsuit alleges that GRAIL defendants made misleading statements and concealed adverse facts about the company's NHS-Galleri trial results, leading to a significant stock price drop.

FinanceLife Sciences
Published
24 Jul 2026 17:12
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.1% · 20.5d old
Duplicates
1 consolidated
#2644Tone
PR NewswireDirect company coverageStored article

HAGENS BERMAN, SOBOL SHAPIRO LLP ALERT: GRAIL, Inc. (NASDAQ: GRAL) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 4, 2026 Lead Plaintiff Deadline

Hagens Berman Sobol Shapiro LLP has filed a securities fraud class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) following a significant stock price drop. The lawsuit alleges that GRAIL and its executives misled investors about the clinical design and efficacy of its NHS-Galleri cancer screening trial, specifically regarding a three-year follow-up period that proved insufficient. Investors who purchased GRAL stock between May 13, 2025, and February 19, 2026, and incurred substantial losses, have until August 4, 2026, to seek lead plaintiff status.

FinanceFinancial MarketsLife Sciences
Published
24 Jul 2026 12:12
News subject
Regulatory and legal
Why this score
Legal victory, Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.1% · 20.7d old
Duplicates
3 consolidated
#2725Tone
GlobeNewswireDirect company coverageStored article

$GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law

A securities fraud class action lawsuit has been filed against GRAIL, Inc. (NASDAQ:GRAL) due to a 50% stock dive following allegations that the company misrepresented results from its NHS-Galleri cancer trial. The lawsuit claims GRAIL misled investors regarding the trial's effectiveness and its ability to achieve its primary endpoint of reducing late-stage cancers within the stated three-year timeframe. Investors are encouraged to contact BFA Law to discuss their legal options, with a lead plaintiff deadline of August 4, 2026.

Life SciencesFinanceFinancial Markets
Published
24 Jul 2026 10:12
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.6% · 20.8d old
Duplicates
1 consolidated
#2837Tone
Stock Traders DailyDirect company coverageStored article

How Grail Inc Com (GRAL) Affects Rotational Strategy Timing

The article analyzes Grail Inc Com (GRAL) through a quantitative research lens, highlighting weak near-term sentiment that could precede shifts in its mid and long-term outlook. It identifies resistance levels and an exceptional short setup with significant downside potential against low risk. Several institutional trading strategies, including position, momentum, and risk hedging, are detailed along with multi-timeframe signal analysis to guide investors.

Financial MarketsLife Sciences
Published
24 Jul 2026 03:10
News subject
Guidance
Why this score
Negative financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 0.8% · 21.1d old
Duplicates
1 consolidated
#2914Tone
The National Law ReviewDirect company coverageStored article

GRAL INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP reminds investors of a securities class action lawsuit against Grail, Inc. (GRAL) with a lead plaintiff deadline of August 4, 2026. The lawsuit alleges that Grail made misleading statements regarding the success of its NHS-Galleri cancer detection trial, which resulted in a significant stock price drop. Investors who purchased GRAL securities between May 13, 2025, and February 19, 2026, and suffered losses are encouraged to contact the law firm.

FinanceLife Sciences
Published
24 Jul 2026 01:10
News subject
Regulatory and legal
Why this score
Legal or regulatory risk, Negative market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 2.1% · 21.2d old
Duplicates
1 consolidated
#3021Tone
GlobeNewswireDirect company coverageStored article

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL) alleging violations of federal securities laws. The lawsuit claims that Grail and its officers made false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, thereby harming investors who purchased securities between May 13, 2025, and February 19, 2026. Investors are encouraged to join the lawsuit, with a lead plaintiff deadline of August 4, 2026.

FinanceLife Sciences
Published
23 Jul 2026 16:09
News subject
Regulatory and legal
Why this score
Legal or regulatory risk
Company focus
Main company · 100%
How it is used
Direct company coverage
Weighted influence
Low · 1.7% · 21.5d old
Duplicates
2 consolidated

Earlier company news

GRAL news archive

Showing 1-14 of 14 stored headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Provider matches checked

Provider mentions not used in the score

3 not scored

A news provider linked these stories to GRAL, but the headline and available text are not mainly about GRAIL, LLC. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of GRAL sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context